Compare Dicks Sporting Goods Inc (DKS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Johnson & Johnson — how do they compare? Dicks Sporting Goods Inc trades at $135.83 (market cap $13.26B), while Johnson & Johnson trades at $260.76 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 46.6× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Johnson & Johnson for 129 Days on average.
| DKS | JNJ | |
|---|---|---|
Market Cap | $13.26B | $618.09B |
Volume | 2,292,035 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $278.43 |
52-Week Low | $121.15 | $186.00 |
Typical Hold Time | 19 Days | 129 Days |
Enterprise Value | $20.31B | $646.37B |
Dividend Yield | 3.71% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.
While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
